CClinicalTrials.gg
Sign In
RecruitingNCT07275190Updated Dec 10, 2025

The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome

An interventional study of Blood draw for the laboratory assessment in EGPA - Eosinophilic Granulomatosis With Polyangiitis and HES - Hypereosinophilic Syndrome, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2025, registered Nov 2025).
  • Started Jun 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to collect clinical, laboratory, and instrumental data from patients with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome, which will then be analyzed using artificial intelligence techniques with the aim of identifying characteristics that differentiate the two diseases and can predict the response to the treatment plan.

02

Conditions studied

  • EGPA - Eosinophilic Granulomatosis With Polyangiitis
  • HES - Hypereosinophilic Syndrome
03

In context

Churg-Strauss Syndrome

58 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.

This study's planned enrollment of 60 is below the median of 72 across 29 interventional studies indexed under Churg-Strauss Syndrome.

Browse Churg-Strauss Syndrome studies →

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 255 studies on the registry; 113 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. 18 years of age or over
  2. A diagnosis of EGPA or HES
  3. Willing and able to give informed written consent, or willing to give permission for a nominated friend or relative to provide written informed assent if they are unable to do so because of physical disabilities

Exclusion criteria

Exclusion Criteria:

  1. Lack of a confirmed diagnosis of EGPA or HES.
  2. Other causes of eosinophilia
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Interventions

  • ProcedureBlood draw for the laboratory assessment

    Blood draw for the laboratory assessment

06

What researchers measure

Primary outcomes

  1. characteristics that are different between HES and EGPA

    Time frame: 18months

07

Study locations

1 of 1 sites recruiting
  • Fondazione IRCCS Policlinico San Matteo, SC Reumatologia
    Pavia, 27100, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275190
Lead sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Responsible party
Carlomaurizio Montecucco (MD, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Dec 10, 2025
Start date
Jun 1, 2025
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 10, 2025

Study contacts

Carlomaurizio Montecucco
Contact
carlomaurizio.montecucco@unipv.it
390382502948
Alessandra Milanesi
Contact
al.milanesi@smatteo.pv.it
0382502498

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Churg-Strauss Syndrome→

Other studies from this sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Start the discussion